ECTRIMS 2023 | iPSC-based tool for CNS antibody detection in multiple sclerosis

Amandine Mathias, PhD, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, delves into the innovative use of induced pluripotent stem cells (iPSCs) as a source of naturally presented central nervous system (CNS) human antigens. Dr Mathias emphasizes the platform’s potential in recognizing antibodies in cerebrospinal fluid and serum from patients with various CNS disorders, including multiple sclerosis. One motivation behind this approach is to circumvent interspecies limitations observed in current models. Dr Mathias asserts that iPSCs provide an abundant and replicable source of naturally presented antigens, ensuring accuracy in antibody detection. Furthermore, the natural presentation of these antigens, considering their 3D conformation and post-translational modifications, is integral for precise antibody recognition. Preliminary results from their research seem promising and have the potential to benefit the broader medical community. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.